Future research should focus on refining these therapeutic strategies through a better understanding of the molecular mechanisms underlying IL-8 signalling in PCa, optimizing dosing regimens, and developing robust biomarkers to guide treatment. The gene discussed is CXCL8; the disease is posterior cortical atrophy.